Logo image of AKRO

AKERO THERAPEUTICS INC (AKRO) Stock Fundamental Analysis

USA - NASDAQ:AKRO - US00973Y1082 - Common Stock

53.84 USD
+0.18 (+0.34%)
Last: 10/17/2025, 8:00:00 PM
53.84 USD
0 (0%)
After Hours: 10/17/2025, 8:00:00 PM
Fundamental Rating

2

Overall AKRO gets a fundamental rating of 2 out of 10. We evaluated AKRO against 536 industry peers in the Biotechnology industry. While AKRO seems to be doing ok healthwise, there are quite some concerns on its profitability. AKRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AKRO has reported negative net income.
AKRO had a negative operating cash flow in the past year.
In the past 5 years AKRO always reported negative net income.
AKRO had a negative operating cash flow in each of the past 5 years.
AKRO Yearly Net Income VS EBIT VS OCF VS FCFAKRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

AKRO has a Return On Assets of -25.60%. This is in the better half of the industry: AKRO outperforms 72.39% of its industry peers.
AKRO has a better Return On Equity (-27.68%) than 79.48% of its industry peers.
Industry RankSector Rank
ROA -25.6%
ROE -27.68%
ROIC N/A
ROA(3y)-29.36%
ROA(5y)-33.72%
ROE(3y)-32.08%
ROE(5y)-37.29%
ROIC(3y)N/A
ROIC(5y)N/A
AKRO Yearly ROA, ROE, ROICAKRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AKRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AKRO Yearly Profit, Operating, Gross MarginsAKRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for AKRO has been increased compared to 1 year ago.
AKRO has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AKRO has an improved debt to assets ratio.
AKRO Yearly Shares OutstandingAKRO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
AKRO Yearly Total Debt VS Total AssetsAKRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 29.49 indicates that AKRO is not in any danger for bankruptcy at the moment.
AKRO has a better Altman-Z score (29.49) than 93.28% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that AKRO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.02, AKRO is in line with its industry, outperforming 42.35% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 29.49
ROIC/WACCN/A
WACCN/A
AKRO Yearly LT Debt VS Equity VS FCFAKRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

AKRO has a Current Ratio of 12.66. This indicates that AKRO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AKRO (12.66) is better than 86.01% of its industry peers.
A Quick Ratio of 12.66 indicates that AKRO has no problem at all paying its short term obligations.
AKRO has a Quick ratio of 12.66. This is amongst the best in the industry. AKRO outperforms 86.01% of its industry peers.
Industry RankSector Rank
Current Ratio 12.66
Quick Ratio 12.66
AKRO Yearly Current Assets VS Current LiabilitesAKRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for AKRO have decreased strongly by -11.44% in the last year.
EPS 1Y (TTM)-11.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AKRO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.74% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.54%
EPS Next 2Y-7.43%
EPS Next 3Y-11.03%
EPS Next 5Y20.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AKRO Yearly Revenue VS EstimatesAKRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
AKRO Yearly EPS VS EstimatesAKRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AKRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AKRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AKRO Price Earnings VS Forward Price EarningsAKRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AKRO Per share dataAKRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A cheap valuation may be justified as AKRO's earnings are expected to decrease with -11.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.43%
EPS Next 3Y-11.03%

More info and screens

0

5. Dividend

5.1 Amount

AKRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AKERO THERAPEUTICS INC

NASDAQ:AKRO (10/17/2025, 8:00:00 PM)

After market: 53.84 0 (0%)

53.84

+0.18 (+0.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners106.92%
Inst Owner Change-0.01%
Ins Owners1.24%
Ins Owner Change0.83%
Market Cap4.32B
Analysts84.21
Price Target75.76 (40.71%)
Short Float %12.72%
Short Ratio8.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.32%
Min EPS beat(2)5.55%
Max EPS beat(2)9.09%
EPS beat(4)3
Avg EPS beat(4)4.11%
Min EPS beat(4)-13.96%
Max EPS beat(4)15.77%
EPS beat(8)5
Avg EPS beat(8)2.58%
EPS beat(12)8
Avg EPS beat(12)5.36%
EPS beat(16)11
Avg EPS beat(16)6.15%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.42%
PT rev (3m)-4.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.83%
EPS NY rev (1m)3.05%
EPS NY rev (3m)6.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.2
P/tB 4.2
EV/EBITDA N/A
EPS(TTM)-3.8
EYN/A
EPS(NY)-4.33
Fwd EYN/A
FCF(TTM)-3.16
FCFYN/A
OCF(TTM)-3.16
OCFYN/A
SpS0
BVpS12.82
TBVpS12.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.6%
ROE -27.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.36%
ROA(5y)-33.72%
ROE(3y)-32.08%
ROE(5y)-37.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.66
Quick Ratio 12.66
Altman-Z 29.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.17%
EPS Next Y1.54%
EPS Next 2Y-7.43%
EPS Next 3Y-11.03%
EPS Next 5Y20.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-37.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.39%
EBIT Next 3Y-18.12%
EBIT Next 5YN/A
FCF growth 1Y-160.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-160.44%
OCF growth 3YN/A
OCF growth 5YN/A